Introduction {#Sec1}
============

Bisphosphonates (BPs) are important drugs in the treatment of neoplasia involving the bones. Particularly in multiple myeloma (MM) they are able to inhibit disease progression and even to prolong survival (Coleman et al. [@CR4]). BPs are usually administered on a regular basis and often concomitantly with antineoplastic drugs such as thalidomide ore lenalidomide. However, in patients with infections involving the jaw, the administration of BPs can be complicated by a bisphosphonate related osteonecrosis of the jaw (BRONJ), a localized death of bone tissue with minor soft tissue involvement (Lee et al. [@CR12]). Rarely, this severe complication can be further worsened by a necrotizing fasciitis (NF), a rapidly progressing infection characterized by extensive necrosis of subcutaneous tissue and fascia (Sultan et al. [@CR17]; Tsitsilonis et al. [@CR18]). If not promptly diagnosed and treated it can lead to a life-threatening condition.

Case description {#Sec2}
================

A 59-year-old woman was diagnosed with a Stage III MM IgA kappa. First line treatment consisted of three cycles of VAD (vincristine, doxorubicin and dexamethasone) followed by autologous stem cell transplant. Since the patient achieved only a partial remission, 5 months later she underwent 6 cycles of bortezomib monotherapy followed by radiation therapy of the whole dorsal column and pelvis. Having achieved a very good partial remission, monthly Ibandronate 6 mg and weekly 20 mg dexamethasone were delivered as maintenance treatment. Before and during BP treatment, the patient underwent a dental examination.

Two years later she presented with M-component in serum and urine, anemia and multiple lytic lesions. Therefore, second line treatment consisting of lenalidomide 25 mg/die, day 1--21 q28 and dexamethasone 25 mg/die p.o., Days 1--4, 8--11, 18--21) was initiated (Weber et al. [@CR21]; Dimopoulos et al. [@CR6]), while the BP was continued. After three cycles the patient presented swelling on the right part of the neck (from Robbinson level I to IV), difficulty in swallowing and acute pain. Intra-oral exploration revealed palato-pharyngeal paralysis on the right side and an ulcer of the right genua-mandibular mucosa with exposure of the surrounding alveolar bone. Within 24 to 48 hours from onset, local erythema, pain and edema quickly worsened. The skin appeared shiny and tense. The patient developed signs of systemic infection as well as atrial fibrillation. Routine laboratory tests revealed high levels of white blood cell count, creatine, C-reactive protein (CRP), and creatine kinase (CK). Magnetic resonance imaging (MRI) study of head and neck showed an increased signal of the right mandibular body, consistent with the diagnosis of right jaw osteonecrosis (Figure [1](#Fig1){ref-type="fig"}A), and a second high-intensity area characterized by gas formation spread for about 10 cm with involvement of the right parapharyngeal space and with extension to skin and muscle, suggestive of a gas-forming necrotising fasciitis of the neck (Figure [1](#Fig1){ref-type="fig"}B). Extension of the abscess was measured by computed tomography (CT) and ranged from the right side of the neck midline located at almost 1.5 cm from the cranial base to the upper edge of the right clavicle. The mediastinum was not involved. Surgical debridement with radical excision of necrotic tissues was necessary and histological examination revealed a lymphohistocytic infiltrate of the dermis, suppuration, necrosis of the superficial fascia, and edema in the fascial planes. Microbiological tissue cultures were positive for Streptococcus Mitis, a facultative anaerobe gram positive coccus that inhabits the human mouth. Combined antibiotic and antifungal therapy associated with nonsteroidal anti-inflammatories was initiated. Despite opioid-based pain therapy, total parenteral nutrition was necessary. In order to accelerate the healing process and because of the anaerobic infection, she underwent 12 sessions of hyperbaric oxygen therapy (OTI). Three months later pain was completely resolved and she was able to eat normally.Figure 1**Magnetic resonance imaging (MRI) study of head and neck. A**, Axial MRI scan showing a significantly increased signal of the bone marrow lesion (yellow arrow) when compared with left mandibular body (asterisk), with bone edema indicative of an inflammatory process taking place in the right mandibular body and gas tracking along the two pterygoid muscles (white arrows). **B**, A coronal T2-weighted image of the submandibular region showing a wide mass with very high signal intensity from the parapharyngeal space to the inferior cervical region with associated edema.

Discussion {#Sec3}
==========

BRONJ is a severe complication of BPs therapy, not depending on the type of drug but on the duration of therapy since it accumulates in the bone tissue. Despite several cases of BRONJ having been reported (Lee et al. [@CR12]), the pathophysiology of this complication is still unknown. However, a multifactorial genesis is strongly suggested. Recently, Vermeer et al. ([@CR19]) have shown that osteoclasts of the jaw and their precursors internalize a greater quantity of BPs compared to those of other bones. Since the inhibition of osteoclasts is dose dependent (Lam et al. [@CR11]), bone remodeling is more reduced in the jaw than elsewhere in the body. Another effect of BPs is to promote a premature senescence of the oral keratinocytes (Kim et al. [@CR9]), impairing mucosal wound healing. Moreover BPs have antiangiogenic activity (Wood et al. [@CR22]; Vincenzi et al. [@CR20]) due to the reduction of circulating endothelial cells (Allegra et al. [@CR1]) and by lowering VEGF serum levels (Santini et al. [@CR14]). Beside BPs therapy, also corticosteroids, immunomodulatory drugs and chemotherapeutic agents have been implicated in the development of BRONJ (Saad et al. [@CR13]) since most patients who have developed BRONJ have been treated with one or both. For example, thalidomide, an efficient antimyeloma agent,(Bamias and Dimopoulos [@CR2]; Goranova-Marinova et al. [@CR7]) has not only immunomodulary effects but also antiangiogenic activity contributing to impaired wound healing. Overall, the immunosuppressive effects of chemo- and radiotherapy, impaired bone remodeling due to corticoid therapy, and reduced vascularization due immunomodulatory drugs (IMiDs) are BRONJ favoring conditions (Goranova-Marinova et al. [@CR7]).

In the present case, BRONJ was further complicated by NF, probably due to an over-infection of the necrotic tissue with successive extension to the surrounding structures. NF is a rare, rapidly progressing infection, characterized by extensive necrosis of subcutaneous tissue and fascia, usually accompanied by severe systemic symptoms (Sultan et al. [@CR17]). It can occur de novo after inoculation of bacteria or as a complication of surgery or other traumas. Most frequent infectious agents are group A β-hemolytic streptococci, hemolytic staphylococcus, and Pseudomonas (Tsitsilonis et al. [@CR18]). Although NF can occur in young and healthy patients, it usually afflicts elderly and/or immunocompromised patients. Early recognition of NF may be difficult because the initial clinical presentation is not specific and often resembles that of cellulitis (Chelsom and Halstensen [@CR3]). An appropriate differential diagnosis between these two pathological conditions is critical for an effective clinical management. Indeed, while cellulitis, which is restricted to the subcutaneous tissue and can be cured in most cases with antibiotics alone, NF instead frequently requires an additional surgical intervention. The gold standard for the diagnosis of NF is a biopsy before surgery (Stamenkovic and Lew [@CR16]). However, this procedure is invasive and can be associated with complications, therefore MR seems to be a valid alternative (Kim et al. [@CR10]). Both cellulitis and NF present a high signal intensity of subcutaneous tissue on T2-weighted images and a moderate to high contrast enhancement of the subcutaneous fat, but only in NF is there a deep fascia involvement identified in T2-weighted and contrast-enhanced T1-weighted images (Kim et al. [@CR10]). Moreover, as was the case with the herein presented patient, laboratory parameters such as CRP and CK could aid in early NF recognition since levels are higher in patients with NF than in those with cellulitis (Simonart et al. [@CR15]). As in BRONJ, the combination of BPs anti-angiogenetic activity and lenalidomide, as well as the immunomodulatory effect of the latter could predispose the patient to NF. The vascular impaired and reduced viability of oral keratinocite slow down the reparative processes in the oral cavity and appear as predisposing factors in mucosal breakdown, facilitating bacteria infiltration. Moreover, patients with MM undergoing lenalidomide have an altered function of the immune system, promoting the extension of the infection. Indeed, Hsu et al. demonstrated that lenalidomide, in combination with dexamethasone (Len-Dex), leads to progressive reduction in the function of NK cells during the course of therapy (Hsu et al. [@CR8]). As recently reported and similarly to our case, lenalidomide induced alterations of physiologic mechanisms can occur within a few days of the beginnig of treatment (Danbara et al. [@CR5]).

The herein presented patient suffered from BRONJ followed by NF, both rare complications. Up to now their pathogenetic causes are not fully understood but a multifactorial genesis is strongly suggested. Available data implicates a major role of altered bone remodeling, reduced angiogenesis and therefore defective tissue repair mechanisms, altered microenviroment and immunodeficiency caused by antimyeloma therapy as well as the disease itself.

Consent {#Sec4}
=======

Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
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